Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517538 | 0.88 | MCL1 (0.40) | MCL1F2RL3DYRK1ACYP1A2CYP3A4 | |
| SCHEMBL20340627 | 0.84 | MCL1 (0.50) | MCL1DYRK1ACYP2D6 | |
| SCHEMBL20340633 | 0.81 | MCL1 (0.50) | MCL1CYP1A2 | |
| SCHEMBL20340617 | 0.80 | MCL1 (0.48) | MCL1PTPN1L3MBTL1 | |
| SCHEMBL20340621 | 0.79 | MCL1 (0.52) | MCL1 | |
| SCHEMBL17517534 | 0.79 | MCL1 (0.47) | MCL1 | |
| SCHEMBL17517537 | 0.76 | MCL1 (0.47) | MCL1 | |
| SCHEMBL28127476 | 0.76 | GRIK2 (0.54) | MCL1DYRK1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17102969 | 0.74 | MAOA (0.51) | MCL1CYP2D6 | |
| SCHEMBL17102971 | 0.73 | MAOA (0.53) | MCL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | MCL1 209/4885PTPN1 4740/4885F2RL3 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.